Clinicogenomic predictors of outcomes in patients with hepatocellular carcinoma treated with immunotherapy.

ABSTRACT:

Introduction

Immune checkpoint inhibitor (ICI) combinations extend overall survival (OS) while anti-PD-1/L1 monotherapy is non-inferior to sorafenib in treatment-naïve, patients with advanced hepatocellular carcinoma (HCC). Clinicogenomic features are posited to influence patient outcomes.

Methods

The primary objective of this retrospective study was to define the clinical, pathologic, and genomic factors associated with outcomes to ICI therapy in patients with HCC. Patients with histologically confirmed advanced HCC treated with ICI at Memorial Sloan Kettering Cancer Center from 2012 to 2022 were included. Association between clinical, pathological, and genomic characteristics were assessed with univariable and multivariable Cox regression model for progression-free surviva

SUBMITTER: Cowzer D 

PROVIDER: S-EPMC11448888 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature